Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal

Biotech Has At Least Eight Major Partners

 
• By Mandy Jackson
  
Skyhawk's lead in-house drug candidate is also for a neurological indication, Huntington's disease (Shutterstock)

More from Deals

More from Business